Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Related Citations for PubMed (Select 24423326)

1.

Update: the status of clinical trials with kinase inhibitors in thyroid cancer.

Wells SA Jr, Santoro M.

J Clin Endocrinol Metab. 2014 May;99(5):1543-55. doi: 10.1210/jc.2013-2622. Epub 2014 Jan 13. Review.

PMID:
24423326
2.

Update on thyroid cancer treatment.

Regalbuto C, Frasca F, Pellegriti G, Malandrino P, Marturano I, Di Carlo I, Pezzino V.

Future Oncol. 2012 Oct;8(10):1331-48. doi: 10.2217/fon.12.123. Review.

PMID:
23130931
4.

[The mitogen-activated protein kinase (MAPK) signaling pathway in papillary thyroid cancer. From the molecular bases to clinical practice].

Zafon C, Obiols G.

Endocrinol Nutr. 2009 Apr;56(4):176-86. doi: 10.1016/S1575-0922(09)70982-9. Epub 2009 Jun 11. Review. Spanish.

PMID:
19627734
5.

Targeted molecular therapies in thyroid carcinoma.

Romagnoli S, Moretti S, Voce P, Puxeddu E.

Arq Bras Endocrinol Metabol. 2009 Dec;53(9):1061-73. Review.

6.

New therapeutic options for advanced forms of thyroid cancer.

Bernet V, Smallridge R.

Expert Opin Emerg Drugs. 2014 Jun;19(2):225-41. doi: 10.1517/14728214.2014.894017. Epub 2014 Mar 3. Review.

PMID:
24588376
7.
8.

Clinical development of kinase inhibitors for the treatment of differentiated thyroid cancer.

Ho AL, Sherman E.

Clin Adv Hematol Oncol. 2011 Jan;9(1):32-41. Review.

PMID:
21326144
9.

Emerging molecular therapies of advanced thyroid cancer.

Catalano MG, Poli R, Pugliese M, Fortunati N, Boccuzzi G.

Mol Aspects Med. 2010 Apr;31(2):215-26. doi: 10.1016/j.mam.2010.02.006. Epub 2010 Feb 20. Review.

PMID:
20176050
10.

New perspectives on the treatment of differentiated thyroid cancer.

Coelho SM, Carvalho DP, Vaisman M.

Arq Bras Endocrinol Metabol. 2007 Jun;51(4):612-24. Review.

11.

Targeted therapies for advanced thyroid cancer.

Puxeddu E, Romagnoli S, Dottorini ME.

Curr Opin Oncol. 2011 Jan;23(1):13-21. doi: 10.1097/CCO.0b013e328340cf94. Review.

PMID:
21045687
12.

[Advances in the treatment of thyroid cancer in the era of molecularly targeted therapies].

Malouf G, Baudin E, Soria JC, Schlumberger M.

Bull Cancer. 2009 Jan;96(1):95-101. doi: 10.1684/bdc.2008.0798. Review. French.

PMID:
19211364
13.

Vandetanib and the management of advanced medullary thyroid cancer.

Campbell MJ, Seib CD, Gosnell J.

Curr Opin Oncol. 2013 Jan;25(1):39-43. doi: 10.1097/CCO.0b013e32835a42b9. Review.

PMID:
23202050
14.

KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2010;10(25):1-49. Epub 2010 Dec 1.

15.

Tyrosine kinase inhibitors and the thyroid.

Sherman SI.

Best Pract Res Clin Endocrinol Metab. 2009 Dec;23(6):713-22. doi: 10.1016/j.beem.2009.08.001. Review.

PMID:
19942148
16.

Role of surgeons in clinical trials for thyroid cancer.

You YN, Wells SA Jr.

World J Surg. 2007 May;31(5):987-95. Review.

PMID:
17426898
17.

Targeted therapy for endocrine cancer: the medullary thyroid carcinoma paradigm.

Ye L, Santarpia L, Gagel RF.

Endocr Pract. 2009 Sep-Oct;15(6):597-604. doi: 10.4158/EP09148.RAR. Review.

PMID:
19546050
18.

Target therapies for radioiodine refractory advanced thyroid tumors.

Schlumberger M.

J Endocrinol Invest. 2012;35(6 Suppl):40-4. Review.

PMID:
23014073
19.

Molecular events in follicular thyroid tumors.

Kroll TG.

Cancer Treat Res. 2004;122:85-105. Review.

PMID:
16209039
20.

Recurrent thyroid cancer: a molecular-based therapeutic breakthrough.

Lalami Y, Awada A.

Curr Opin Oncol. 2011 May;23(3):235-40. doi: 10.1097/CCO.0b013e3283448206. Review.

PMID:
21330922
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk